PRODUCT TYPES – Page 27

Biosimilar process change without bridging study during commercial launch readiness: decision tree for lab method variability vs true product differences

Recognizing signals on the production floor or in the lab can provide early warnings of potential issues with biosimilars. These symptoms often manifest as unexpected variability in analytical results, inconsistent…

Supply interruption risk during lifecycle management: FDA/EMA communication strategy

The first step in addressing supply interruption risks involves identifying symptoms or signals that indicate potential issues. These can arise from various sources such as quality control, production areas, or…

Biosimilar charge variant profile drift during CPV trending review: risk assessment for critical quality attributes and clinical impact

Timely recognition of symptoms related to charge variant profile drift is paramount. Key signals may include:Click to read the full article.

Supply interruption risk during inspection readiness: CAPA with limited data sets

Supply interruptions may trigger a range of symptoms within both manufacturing and laboratory environments. Recognizing these symptoms early can significantly enhance response effectiveness. Common signals include:Click to read the full…

Biosimilar potency OOS vs reference product during comparability protocol execution: FDA/EMA expectations for root cause, rework, and comparability justification

Identifying signals indicating potential issues with biosimilar potency is crucial for timely intervention. Symptoms of OOS during comparability testing may include:Click to read the full article.

Method variability OOS during small-batch manufacturing: CAPA with limited data sets

Identifying the symptoms of method variability OOS before it manifests into larger issues is crucial. Symptoms may include:Click to read the full article.

Biosimilar method transfer failure across labs during FDA/EMA scientific advice / meetings: bridging study planning and regulatory communication strategy

Identifying symptoms or signals indicative of a biosimilar method transfer failure requires vigilant monitoring across multiple facets of the laboratory and manufacturing environment. Symptoms may manifest as:Click to read the…

Specification justification gap during small-batch manufacturing: CAPA with limited data sets

Identifying symptoms that indicate a specification justification gap is crucial in the early stages of deviation detection. Signals that might suggest this issue include:Click to read the full article.

Biosimilar reference standard qualification gap during biosimilar development: risk assessment for critical quality attributes and clinical impact

Identifying signals that indicate potential qualification gaps in the biosimilar development process is essential. Symptoms may manifest in various ways:Click to read the full article.

Stability failure with limited batches during lifecycle management: CAPA with limited data sets

Recognizing the symptoms of a stability failure is paramount for swift action. Common signals to watch for include:Click to read the full article.

Biosimilar functional assay variability (cell-based assay) during commercial launch readiness: FDA/EMA expectations for root cause, rework, and comparability justification

Recognizing signs of assay variability is the first critical step in managing quality control within biosimilar manufacturing. Some common symptoms that may indicate functional assay variability include:Click to read the…

Method variability OOS during regulatory review: FDA/EMA communication strategy

Identifying symptoms or signals of method variability OOS starts with vigilant monitoring during the analytical phase of product development and quality control. Common indicators include:Click to read the full article.